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Introduction {#sec007}
============

Social networks of family, friends, neighbours, work colleagues, acquaintances, and others have significant impact on our health, health behaviours \[[@pmed.1002890.ref001]--[@pmed.1002890.ref004]\], and our ability to change behaviours. However, even though these networks are pervasive in the course of daily life, they have seldom been harnessed in studies of health behaviour interventions \[[@pmed.1002890.ref005],[@pmed.1002890.ref006]\]. Most existing interventions continue to focus on individual-level behaviour and beliefs and fail to address the influential role of an individual's social systems and environments. In recent years, there has been a growing interest in understanding the effects of social networks on health behaviour, which has been accelerated by the emerging prominence of complexity or systems science in public health \[[@pmed.1002890.ref007]\].

Significant developments in our understanding of the structure, characteristics, and function of social networks, and the impact they have on health, have provided opportunities for novel interventions to improve the health of individuals, communities, and populations. Social network interventions specifically use or alter the characteristics of social networks to generate, accelerate, or maintain health behaviours and positive health outcomes \[[@pmed.1002890.ref008]\]. Such approaches have the potential to support various types of health promotion efforts (e.g., health communication, family, or organisational approaches) and to increase the reach or enhance the effectiveness of existing interventions. A landmark paper by Valente (2012) \[[@pmed.1002890.ref008]\] set out a taxonomy of social network intervention approaches. Four approaches were detailed: (1) those that engage individuals who are selected on the basis of some network property and who may have greater roles in providing information or support within their network (see example by Campbell and colleagues \[2008\] \[[@pmed.1002890.ref009]\]); (2) those that engage certain groups of people (an approach known as segmentation; see example by Buller and colleagues \[1999\] \[[@pmed.1002890.ref010]\]); (3) those that encourage or enhance peer-to-peer interactions to cascade information and effects to other network members (a process known as induction; see example by Hoffman and colleagues \[2013\] \[[@pmed.1002890.ref011]\]); and (4) those that involve changing the network (alteration) by adding or deleting members, adding or deleting specific social ties, or changing the entire network (see example by Litt and colleagues \[2007\] \[[@pmed.1002890.ref012]\]). Such approaches can improve the efficiency and effectiveness of public health interventions because they leverage important mechanisms for behaviour change (e.g., the influence of social norms, social learning, and social support) \[[@pmed.1002890.ref013]\] and potentially enhance behaviour change maintenance \[[@pmed.1002890.ref014]\].

Although research in social networks dates back to the 1930s, social networks are not routinely considered in public health interventions. Extant research has largely focused on observational \[[@pmed.1002890.ref001]--[@pmed.1002890.ref004]\] and simulation studies \[[@pmed.1002890.ref015]--[@pmed.1002890.ref017]\]. Observational studies have identified features of social networks associated with health behaviours or outcomes that may be important targets for interventions, and simulation studies have begun to explore the potential impact of using social network characteristics for behaviour change \[[@pmed.1002890.ref017]\]. However, real-world interventions that use social networks are less common.

Previous systematic reviews and meta-analyses have provided evidence to support the effectiveness of social network interventions for some specific health outcomes. A meta-analysis by Spencer-Bonilla and colleagues (2017) \[[@pmed.1002890.ref018]\] involving 19 randomised controlled trials (RCTs) investigated the effectiveness of social network interventions on social support, glycaemic control, and quality of life in patients with type 2 diabetes. Results demonstrated that interventions improved social support (0.74 SD \[95% CI 0.32--1.15\]) and haemoglobin A1c (HbA1c) at 3 months (−0.25 percentage points \[95% CI −0.40 to −0.11\]) but not quality of life. However, the few trials identified had a high risk of bias. A systematic review by Wang and colleagues (2011) \[[@pmed.1002890.ref019]\] focused solely on condom use. Among the nine included studies with control groups, eight showed significant improvements in at least one measure of condom use. Therefore, there is a need to further investigate the effectiveness of social network interventions for a range of other health behaviours and outcomes including drug use, diet, physical activity, screening, vaccinations, etc. There is also a need to explore the impact of different network intervention approaches, as this has not been done in other reviews and would further advance our understanding of how network interventions operate. Also, these previous reviews mostly included dyadic-level approaches involving spouses or pairs of other family members, emphasising the need for a review that focuses on network interventions that move beyond the dyad level.

The explicit use of social network data, which map the structure of social connections among multiple people, distinguishes social network interventions from the large body of general peer support and social support interventions that have been extensively studied and that typically focus on individuals' perceptions of social phenomena (e.g., social norms) or on dyads \[[@pmed.1002890.ref020]\]. As such, the optimal way to apply the myriad of social network intervention approaches to various health interventions remains unknown. For example, it is not clear who in a social network should be engaged to catalyse the diffusion of behaviour change, nor which mechanisms can best be harnessed to maximise the effects of an intervention, though some have suggested using theory as a guide \[[@pmed.1002890.ref006]\]. The present study addresses this gap through a systematic review and meta-analysis of studies that aimed to harness social network interventions to improve health behaviours and outcomes (or their surrogates). We also examine whether different network interventions approaches---individual, segmentation, induction, or alteration---vary in their effectiveness.

Methods {#sec008}
=======

Search strategy and selection criteria {#sec009}
--------------------------------------

This study is registered with PROSPERO \[[@pmed.1002890.ref021]\] (International Prospective Register of Systematic Review) (CRD42015023541) and is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) \[[@pmed.1002890.ref022]\].

We searched Medline, Embase, Web of Knowledge, Scopus, Psychinfo, Education Resources Information Center (ERIC), the International Bibliography of the Social Sciences (IBSS), Sociological Abstracts Trial, the Cochrane Central Register of Controlled Trials (CENTRAL), the World Health Organization (WHO) International Clinical Trials Registry Portal (ICTRP), and ClinicalTrials.gov from 1990 until May 28, 2019.

We included randomised trials and controlled before-and-after studies (i.e., study designs that included a control group \[participants were not randomised to groups\] and collected data pre- and postintervention) that compared a social network intervention (whether given alone or in combination with other intervention components) against the following comparators: usual care, no intervention, waiting-list control, or an intervention with no explicit social network component. We included studies that addressed all age groups regardless of health status but limited the studies to those reported in English. Reference lists of relevant studies were also screened. Details of methods and the search strategies are described in [S1 Text](#pmed.1002890.s002){ref-type="supplementary-material"}.

Data extraction and quality assessment {#sec010}
--------------------------------------

Two authors (RFH and KdlH) independently screened the titles and abstracts of retrieved citations to identify potentially relevant studies. The full articles were evaluated if a decision could not be made based on the titles and abstracts. Relevant data were extracted by two reviewers (RFH and JB) using a standardised form and cross-checked. Any discrepancies were resolved by consensus. The extracted data included study characteristics, participant characteristics, interventions, social network functions (see [S1 Text](#pmed.1002890.s002){ref-type="supplementary-material"}), outcomes, and other relevant findings. The Cochrane Risk of Bias assessment tool \[[@pmed.1002890.ref023]\] was used to assess risk of bias (see [S1 Text](#pmed.1002890.s002){ref-type="supplementary-material"}). When publications lacked sufficient detail for full data extraction, we contacted the original authors for the necessary information.

Types of interventions {#sec011}
----------------------

Social network interventions were defined as those that purposefully used social networks or social network data to generate social influence and/or accelerate behaviour change among individuals, communities, organisations, or populations \[[@pmed.1002890.ref008]\]. Interventions could use existing networks, establish new networks, disrupt harmful networks, or use social network data to educate participants about the potential influences of their health behaviours on their network members, including in vivo and online social networks. A broad definition of 'social networks' was employed to encompass social interactions and personal relationships \[[@pmed.1002890.ref024]\], such as with friends, school friends, nonschool friends, family members, sexual partners, work colleagues, neighbours, and networks in which an unhealthy behaviour is shared (such as substance misuse and risky sex practices). The study must have measured social relationships, and that relationship must have been used in some aspect of the intervention design or delivery. The measurement of relationships must have been beyond the dyad level and included ties among multiple actors (i.e., interventions that targeted interactions between spouses or a pair of friends were excluded). Included interventions must have targeted change in health behaviours or health outcomes (or their surrogates). Details of interventions are described in [S1 Text](#pmed.1002890.s002){ref-type="supplementary-material"}. Briefly, individual network interventions included those that specifically used network data to identify certain individuals to be recruited to act as proponents of behaviour change on the basis of some network property. Segmentation network interventions included interventions directed towards groups of people clustered in a network. Induction network interventions involve excitation and activation of existing social ties in a social network to diffuse information or healthy behaviours. Alteration network interventions involve changing the structure of the network by the addition of new members or breaking existing ties with those who foster and facilitate unhealthy, risky behaviours.

Outcomes {#sec012}
--------

Included studies had a primary outcome of health-related behaviour change using objective or self-report measures (e.g., change in physical activity) or change in a health outcome or relevant proxy/surrogate measure (e.g., diffusion of health promotion information). As well as measures of health outcomes and health behaviours, the study also included behavioural surrogates (e.g., HbA1c) or network surrogates (e.g., reproductive ratio). Details of outcomes are described in [S1 Text](#pmed.1002890.s002){ref-type="supplementary-material"}. A wide range of outcome measures were used in the studies, in keeping with the range of topics investigated. The outcomes related to sexual health, drug risk, weight loss, diet, physical activity, smoking cessation, alcohol/other substance misuse, well-being, change in diabetes marker (HbA1c), mammography screening, ticket redemption for water purification, and reproductive ratio for number of participants installing an app.

Data synthesis and statistical analysis {#sec013}
---------------------------------------

Statistical analyses were done in accordance with our registered protocol (PROSPERO: CRD42015023541) \[[@pmed.1002890.ref021]\]. We conducted meta-analyses according to time point of outcome measurement (≤6 months, 6--12 months, last follow-up) for sexual health outcomes (i.e., percent engaging in condomless sex) and drug risk outcomes (i.e., percent engaging in injection drug risk or other drug risk behaviours). Because of clinical and statistical heterogeneity, we were not able to pool data for other outcomes. Log odds ratios (ORs) and standard errors (SEs) were calculated for each study to provide the odds of achieving a more favourable outcome for the intervention group compared with the control group. When studies reported event (numbers or percentages of participants) and denominators data (*k* = 21) or adjusted ORs and 95% confidence intervals (CIs) (*k* = 6), these were used to directly compute log ORs and SEs. When studies reported ORs and *p*-values, *p*-values were converted to SEs using procedures outlined in the Cochrane handbook (*k* = 1). When studies reported means and SDs, standardised mean differences (SMDs) and SEs were calculated and converted to log ORs and SEs using the Chinn (2000) equation \[[@pmed.1002890.ref025]\] (*k* = 12). When studies reported data separately for multiple intervention groups or subgroups, data were combined using procedures outlined in the Cochrane handbook \[[@pmed.1002890.ref026]\] (*k* = 5). All data were transformed so that higher OR values indicated higher odds of achieving a more favourable outcome for intervention groups compared with controls. A significant intervention effect was determined when the 95% CI excluded 1 for the OR. Separate meta-analyses were carried out for studies reporting (1) sexual health outcomes and (2) drug risk outcomes.

A direct meta-analysis was used to pool ORs using a random-effects model. Heterogeneity was assessed using the Cochran Q test and the I^2^ statistic. Heterogeneity and reporting bias were assessed visually using forest and funnel plots created using Stata \[[@pmed.1002890.ref027]\]. The Egger and colleagues' (1997) \[[@pmed.1002890.ref028]\] and precision-effect estimate with standard error (PEESE) \[[@pmed.1002890.ref029]\] tests for study size effects were used to formally test for publication bias.

We did prespecified subgroup analyses to explore heterogeneity by showing how effect sizes differed between groups of studies. Characteristics included intervention approach (individual, segmentation, induction, alteration), intervention length (≤3 months, 3--6 months, 6--12 months, 12--18 months, \>18 months), age of participants (above or below the overall mean age of 32.4 years across studies), and gender of participants (above or below the mean of 45.5% female across studies). Subgroup analyses were done separately for pooled sexual health outcomes and drug risk outcomes.

We conducted prespecified sensitivity analyses to determine whether the results of the meta-analysis were robust to omission of studies classified at high risk of bias using the Cochrane Risk of Bias tool, studies not performing intention-to-treat (ITT) analyses, studies with attrition rates higher than 20%, and studies using nonrandomised designs. Sensitivity analyses were conducted separately for pooled sexual health outcomes and drug risk outcomes.

A significant intervention effect was determined when the 95% CI for the OR excluded 1.00. Statistical significance was set at the 5% level (*p* \< 0.05). We used Stata release 13 (StataCorp, College Station, TX, United States) \[[@pmed.1002890.ref027]\] for the analyses.

Apart from the additional sensitivity analysis excluding studies using nonrandomised designs, the study was carried out per the prespecified protocol. The subgroup analyses were prespecified prior to commencement of the review and after registration.

Results {#sec014}
=======

We identified 26,503 records, in which 235 potentially eligible articles were reviewed in full text. Of these, 197 were excluded because they did not investigate a social network intervention (*n* = 97), measure a health behaviour or health outcome (*n* = 22), or use our prespecified study design criterion (*n* = 65). This left 37 eligible studies for inclusion in our review. The details of our literature search are reported in [Fig 1](#pmed.1002890.g001){ref-type="fig"}, which shows the PRISMA flow diagram. [Table 1](#pmed.1002890.t001){ref-type="table"} presents a summary of the characteristics of included studies. Further study characteristics include social network functions ([S1](#pmed.1002890.s007){ref-type="supplementary-material"}--[S4](#pmed.1002890.s010){ref-type="supplementary-material"} Tables), risk of bias assessment ([S1 Fig](#pmed.1002890.s011){ref-type="supplementary-material"}), and citations for all included studies ([S2 Text](#pmed.1002890.s003){ref-type="supplementary-material"}).

![PRISMA flow diagram.\
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###### Trials of social network interventions meeting the inclusion criteria.

![](pmed.1002890.t001){#pmed.1002890.t001g}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                                                           Country                                                 Study Design                                                   Population                                                                                              Intervention                                      Control                             Outcome Measure(s)                                                                                                              ≤6 months\           \>6 months to ≤12 months\   Last Follow-up\      Risk of Bias Summary
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           OR (95% CI)          OR (95% CI)                 OR (95% CI)          
  ----------------------------------------------------------------------------------- ------------------------------------------------------- -------------------------------------------------------------- ------------------------------------------------------------------------------------------------------- ------------------------------------------------- ----------------------------------- ------------------------------------------------------------------------------------------------------------------------------- -------------------- --------------------------- -------------------- ----------------------
  **Individual Approach**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Kelly and colleagues, 1997 \[[@pmed.1002890.ref001]\]                               USA                                                     RCT                                                            MSM; mean age 31 years                                                                                  265                                               173                                 Mean number of times engaged in UAI during past 2 months                                                                        \-                   1.62 (0.97--2.71)           \-                   Low

  Latkin and colleagues, 1998 \[[@pmed.1002890.ref002]\]                              USA                                                     Controlled before and after                                    Unemployed inner-city PIDs; aged 25--40 years                                                           *n* = 41 peer leaders; *n* = 78 network members   70                                  \% always cleaning used needle                                                                                                  4.68 (2.20--9.96)    \-                          \-                   High

  Sikkema and colleagues, 2000 \[[@pmed.1002890.ref003]\]                             USA                                                     RCT                                                            Women in low-income, inner-city housing; mean age 35.9 years                                            351                                               339                                 Mean % women reporting any UI in past 2 months                                                                                  \-                   1.43 (1.06--1.94)           \-                   High

  Amirkhanian and colleagues, 2005 \[[@pmed.1002890.ref004]\]                         Russia and Bulgaria                                     RCT                                                            Young MSM; mean age 23 years                                                                            133                                               143                                 \% reporting any UI                                                                                                             2.49 (1.49--4.16)    1.62 (0.97--2.71)           \-                   High

  Kelly and colleagues, 2006 \[[@pmed.1002890.ref005]\]                               Bulgaria                                                RCT                                                            Roma men; mean age 20 years                                                                             145                                               137                                 Occurrence of UI during previous 3 months                                                                                       1.58 (0.94--2.66)    2.39 (1.30--4.38)           \-                   High

  Campbell and colleagues, 2008 \[[@pmed.1002890.ref006]\]                            United Kingdom                                          Cluster RCT                                                    12--13-year-old students                                                                                5,358                                             5,372                               Prevalence of smoking in the past week in school-year group                                                                     1.31 (1.13--1.52)    1.25 (1.11--1.40)           1.19 (1.08--1.31)    Low

  Kim and colleagues, 2015 \[[@pmed.1002890.ref007]\]                                 [\*](#t001fn003){ref-type="table-fn"}Honduras           Cluster RCT                                                    Members of local village; mean age 35 years                                                             3,740                                             1,599                               Proportions of available products redeemed (product adoption) by population under each targeting method                         1.05 (0.95--1.17)    \-                          \-                   Low

  Amirkhanian and colleagues, 2015 \[[@pmed.1002890.ref008]\]                         Russia and Hungary                                      RCT                                                            MSM; mean age 27--29 years                                                                              339                                               287                                 Proportion of any UAI in past 3 months                                                                                          2.17 (1.56--3.02)    1.68 (1.21--2.33)           \-                   High

  Woudenberg and colleagues, 2018 \[[@pmed.1002890.ref009]\]                          The Netherlands                                         Cluster RCT                                                    Healthy adolescents; mean age 12.17 years                                                               118                                               120                                 Mean steps per day (Fitbit Flex)                                                                                                0.90 (0.54--1.51)    \-                          \-                   Low

  **Segmentation Approach**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Trotter and colleagues, 1996 \[[@pmed.1002890.ref010]\]                             USA                                                     RCT                                                            PIDs or crack smokers; 31% aged 18--24 years                                                            189                                               89                                  Composite drug risk (frequency used crack, injected drugs, unbleached needle use); shared cotton, cookers, and/or rinse water   0.80 (0.36--1.74)    \-                          \-                   High

  Kincaid and colleagues, 2000 \[[@pmed.1002890.ref011]\]                             [\*](#t001fn003){ref-type="table-fn"}Bangladesh         Controlled before and after                                    Community-based females; mean age 30 years                                                              107                                               753                                 \% beginning contraception use/continuing contraception use                                                                     \-                   \-                          7.88 (4.94--12.57)   High

  Minnis and colleagues, 2014 \[[@pmed.1002890.ref012]\]                              USA                                                     Cluster RCT                                                    Latino neighbourhood; mean age 17 years                                                                 79                                                83                                  Unprotected sex at last sex                                                                                                     2.38 (0.80--7.11)    \-                          \-                   High

  Shaya and colleagues, 2014 \[[@pmed.1002890.ref013]\]                               USA                                                     Partial RCT                                                    Majority African American population with type 2 diabetes; mean age 53 years                            68                                                70                                  Changes in HbA1c and blood glucose                                                                                              3.61 (1.93--6.75)    \-                          \-                   Low

  Cobb and colleagues, 2014 \[[@pmed.1002890.ref014]\]                                USA                                                     Randomised, placebo-controlled, parallel-group trial           Healthy adults; mean age 47 years                                                                       752                                               751                                 Overall well-being measured by the Individual-Level Well-Being Assessment and Scoring Method (scale: 0--100)                    1.40 (1.11--1.77)    \-                          \-                   High

  **Induction Approach**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Kegeles and colleagues, 1996 \[[@pmed.1002890.ref015]\]                             USA                                                     RCT                                                            MSM; mean age 23 years                                                                                  159                                               109                                 Proportion engaging in any UAI in the past 2 months with men, boyfriends/lovers, nonprimary partners                            \-                   1.54 (0.84--2.82)           \-                   Low

  Latkin and colleagues, 1996 \[[@pmed.1002890.ref016]\]                              USA                                                     Controlled before and after                                    PIDs; median age 40 years                                                                               39                                                50                                  Frequency of needle sharing with HIV-positive and HIV-negative partners                                                         \-                   \-                          1.29 (0.66--2.53)    High

  Buller and colleagues, 1999 \[[@pmed.1002890.ref017]\]                              USA                                                     RCT                                                            Blue-collar employees; mean age 42 years                                                                395                                               371                                 Daily fruit and vegetable intake using 24-hour recall questionnaire                                                             \-                   \-                          1.28 (0.98--1.67)    Low

  Wing and Jeffrey, 1999 \[[@pmed.1002890.ref018]\]                                   USA                                                     RCT                                                            Healthy adults; mean age 43 years                                                                       128                                               38                                  Overall weight loss (months 0--4 and months 0--10)                                                                              1.89 (0.91--3.92)    2.05 (0.97--4.33)           \-                   High

  Elford and colleagues, 2001 \[[@pmed.1002890.ref019]\]                              UK                                                      Controlled before and after                                    Gay men; median age 33 years                                                                            1,646                                             223                                 \% reported UAI in last 3 months                                                                                                0.76 (0.52--1.11)    0.85 (0.57--1.28)           0.77 (0.42--1.44)    High

  Earp and colleagues, 2002 \[[@pmed.1002890.ref020]\]                                USA                                                     Controlled before and after                                    African American women; 45% aged 50--64 years                                                           438                                               467                                 Self-reported mammography in the past 2 years                                                                                   \-                   \-                          0.90 (0.61--1.32)    High

  Flowers and colleagues, 2002 \[[@pmed.1002890.ref021]\]                             UK                                                      Quasi-experimental, two-by-two, repeat cross-sectional trial   Gay men; mean age 32 years                                                                              1,245                                             1,031                               Rate of UAI with casual partners in past year                                                                                   \-                   \-                          1.22 (0.79--1.89)    High

  Latkin and colleagues, 2003 \[[@pmed.1002890.ref022]\]                              USA                                                     RCT                                                            Low-income African American PIDs; mean age 39 years                                                     167                                               83                                  Self-report injection risk behaviours: stopping injection drug use in past 6 months                                             3.65 (1.23--10.83)   \-                          \-                   High

  Morisky and colleagues, 2004 \[[@pmed.1002890.ref023]\]                             [\*](#t001fn003){ref-type="table-fn"}Philippines        Controlled before and after                                    Heterosexual male clients of commercial sex workers; mean age 34.7 years                                1,819                                             1,570                               Self-reported condom use                                                                                                        \-                   \-                          1.36 (1.19--1.56)    High

  Garfein and colleagues, 2007 \[[@pmed.1002890.ref024]\]                             USA                                                     RCT                                                            PIDs; mean age 23 years                                                                                 431                                               423                                 Self-reported injection behaviours in past 3 months (composite variable)                                                        1.56 (1.07--2.27)    \-                          \-                   High

  Valente and colleagues, 2007 \[[@pmed.1002890.ref025]\]                             USA                                                     Cluster RCT                                                    High-risk adolescents; mean age 16 years                                                                351                                               534                                 Change in substance use (cigarettes, alcohol, marijuana, cocaine) (quit rate)                                                   \-                   1.16 (0.65--2.07)           \-                   High

  Latkin and colleagues, 2009 \[[@pmed.1002890.ref026]\]                              USA and [\*](#t001fn003){ref-type="table-fn"}Thailand   RCT                                                            PIDs; 40% aged 40+ years                                                                                550                                               573                                 Frequency of risk behaviours (injected in last month)                                                                           0.70 (0.43--1.12)    \-                          \-                   High

  Sutcliffe and colleagues, 2009 \[[@pmed.1002890.ref027]\]                           [\*](#t001fn003){ref-type="table-fn"}Thailand           RCT                                                            Healthy adults; median age 19 years                                                                     495                                               488                                 Frequency of methamphetamine use in past 3 months                                                                               0.90 (0.67--1.20)    1.09 (0.83--1.43)           \-                   High

  Tobin and colleagues, 2011 \[[@pmed.1002890.ref028]\]                               USA                                                     RCT                                                            PIDs; mean age 44 years                                                                                 114 indexes (163 network members)                 113 indexes (173 network members)   Frequency of sharing needles for injection and drug splitting in past 6 months (injection risk)                                 1.08 (0.53--2.17)    2.13 (1.04--4.35)           2.63 (1.25--5.56)    Low

  Bastian and colleagues, 2013 \[[@pmed.1002890.ref029]\]                             USA                                                     RCT                                                            Current smokers who were family members/close friends of patients with lung cancer; mean age 47 years   245                                               251                                 7-day smoking abstinence                                                                                                        1.20 (0.70--2.06)    0.90 (0.50--1.62)           \-                   Low

  Hoffman and colleagues, 2013 \[[@pmed.1002890.ref030]\]                             Russia                                                  RCT                                                            PIDs and their drug and/or sexual network; median age 28 years                                          99 indexes (127 network members)                  92 indexes (114 network members)    Incidence of HIV infection                                                                                                      \-                   \-                          2.12 (0.86--5.23)    High

  Gotsis and colleagues, 2013 \[[@pmed.1002890.ref031]\]                              USA                                                     Randomised crossover                                           Healthy adults; mean age 36 years                                                                       64 (25 ego networks)                              78 (29 ego networks)                Self-reported physical activity frequency (single-item measure)                                                                 1.46 (0.68--3.17)    \-                          \-                   Low

  Booth and colleagues, 2016 \[[@pmed.1002890.ref032]\]                               [\*](#t001fn003){ref-type="table-fn"}Ukraine            Cluster RCT                                                    PIDs; mean age 32 years                                                                                 611                                               589                                 HIV incidence                                                                                                                   \-                   1.89 (1.41--2.53)           \-                   Low

  Cobb and colleagues, 2016 \[[@pmed.1002890.ref033]\]                                USA                                                     RCT (12-cell fractional factorial design)                      Adult smokers; mean age 44 years                                                                        6,028                                             3,014                               Reproductive ratio: number of individuals installing the app divided by the number of a seed participant's Facebook friends     \-                   1.26 (1.10--1.44)           \-                   Low

  **Alteration Approach**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Wingood and colleagues, 2004 \[[@pmed.1002890.ref034]\]                             USA                                                     RCT                                                            Women living with HIV; mean age 35 years                                                                190                                               176                                 Self-report UVI                                                                                                                 1.10 (0.75--1.61)    1.29 (0.86--1.91)           \-                   Low

  Litt and colleagues, 2007; 2009 \[[@pmed.1002890.ref035],[@pmed.1002890.ref036]\]   USA                                                     RCT                                                            Alcohol dependents; mean age 45 years                                                                   140                                               70                                  Proportion of days of no alcohol use in past 90 days, number of days of continuous alcohol abstinence for 90 days               3.97 (2.26--6.96)    2.90 (1.66--5.06)           1.77 (1.00--3.13)    High

  Eaton and colleagues, 2011 \[[@pmed.1002890.ref037]\]                               USA                                                     Randomised efficacy trial                                      At-risk HIV-negative MSM; mean age 29 years                                                             74                                                75                                  Number UAI with HIV-positive or -negative partners                                                                              1.08 (0.61--1.94)    \-                          \-                   Low

  Graham and colleagues, 2016 \[[@pmed.1002890.ref038]\]                              USA                                                     RCT randomised, controlled factorial design                    Healthy adults; mean age 42 years                                                                       2,640                                             2,650                               Website utilisation metrics (number of watched videos on smoking addiction)                                                     0.92 (0.88--0.96)    \-                          \-                   Low
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

References 1--38: see [S2 Text](#pmed.1002890.s003){ref-type="supplementary-material"}. See [S1](#pmed.1002890.s007){ref-type="supplementary-material"}--[S4](#pmed.1002890.s010){ref-type="supplementary-material"} Tables for further details regarding the network intervention approaches.

\- Outcomes not measured or data not available.

\* Indicates LMIC as reported in the DAC list of ODA recipients 2019.

Abbreviations: CI, confidence interval; DAC, Development Assistance Committee; HbA1c, haemoglobin A1c; HIV, human immunodeficiency virus; LMIC, low- and middle-income country; MSM, men who have sex with men; PID, person who injects drugs; ODA, Official Development Assistance; OR, odds ratio; RCT, randomised controlled trial; UAI, unprotected anal intercourse; UI, unprotected intercourse; UVI, unprotected vaginal intercourse

The mean age of all participants was 32.4 years (SD 12.7), of whom 24,679 (45.5%) were women ([Table 1](#pmed.1002890.t001){ref-type="table"}). The majority of studies addressed human immunodeficiency virus (HIV) prevention behaviours (*n* = 23), including studies involving risky drug use among network partners (e.g., shared needles) and studies of sexual partnership networks. Studies took place mainly in high-income countries (e.g., USA, UK), with only six studies involving low- and middle-income countries (LMICs)---namely, Honduras, Bangladesh, Philippines, Thailand, and Ukraine. The majority of studies predominantly engaged minority populations such as ethnic minority groups (*n* = 5) or men who have sex with men (MSM) (*n* = 7) or those from socio-disadvantaged communities (*n* = 10). Studies typically had an exclusive or prominent focus on one network intervention approach: nine studies used an individuals network intervention approach, five a segmentation approach, 19 an induction approach, and four an alteration approach. The interventions reported in these studies combined behaviour change theories with theories about the influence of networks (see [S1](#pmed.1002890.s007){ref-type="supplementary-material"}--[S4](#pmed.1002890.s010){ref-type="supplementary-material"} Tables). Behaviour change models included social cognitive theory, theory of reasoned action, theory of planned behaviour, health belief model, social norms theories, social influence, socio-ecological model, social learning theory, and social identity theory. For the network elements, the theoretical underpinning most cited was diffusion of innovation theory.

For sexual health (*n* = 7 studies), the pooled OR was 1.46 (95% CI 1.01--2.11; *p* \< 0.05; I^2^ = 76%) at ≤6 months. This indicates a substantial increase in the odds that network interventions will have a lower prevalence of risky sexual health practices compared with the control group at 6 months. At 6--12 months (*n* = 9 studies), the pooled OR was 1.51 (95% CI 1.27--1.81; *p* \< 0.001; I^2^ = 40%). At \>12 months (*n* = 5 studies), the pooled OR was 1.85 (95% CI 0.91--3.74; *p* = 0.09; I^2^ = 93%). See Figs [2](#pmed.1002890.g002){ref-type="fig"}--[4](#pmed.1002890.g004){ref-type="fig"}.

![Forest plot showing odds of a more favourable outcome for intervention groups compared with controls for outcomes reported at ≤6 months (sexual health outcome measures).\
The blue denotes significant effect in favour of the Intervention group. The grey denotes non-significant. The red denotes significant effect in the favour of the control group. CI, confidence interval.](pmed.1002890.g002){#pmed.1002890.g002}

![Forest plot showing odds of a more favourable outcome for intervention groups compared with controls for outcomes reported at \>6 months to ≤12 months (sexual health outcome measures).\
The blue denotes significant effect in favour of the Intervention group. The grey denotes non-significant. The red denotes significant effect in the favour of the control group. CI, confidence interval.](pmed.1002890.g003){#pmed.1002890.g003}

![Forest plot showing odds of a more favourable outcome for intervention groups compared with controls for outcomes reported at last follow-up (sexual health outcome measures).\
The blue denotes significant effect in favour of the Intervention group. The grey denotes non-significant. The red denotes significant effect in the favour of the control group. CI, confidence interval.](pmed.1002890.g004){#pmed.1002890.g004}

For drug risk (*n* = 7 studies), the pooled OR was 1.34 (95% CI 0.86--2.10; *p* = 0.19; I^2^ = 79%) at ≤6 months. At 6--12 months (*n* = 2 studies), the pooled OR was 1.40 (95% CI 0.74--2.64; *p* = 0.30; I^2^ = 66%). At \>12 months (*n* = 2 studies), the pooled OR was 1.81 (95% CI 0.90--3.64; *p* = 0.10; I^2^ = 48%). See Figs [5](#pmed.1002890.g005){ref-type="fig"}--[7](#pmed.1002890.g007){ref-type="fig"}.

![Forest plot showing odds of a more favourable outcome for intervention groups compared with controls for outcomes reported at ≤6 months (drug risk outcome measures).\
The blue denotes significant effect in favour of the Intervention group. The grey denotes non-significant. The red denotes significant effect in the favour of the control group. CI, confidence interval.](pmed.1002890.g005){#pmed.1002890.g005}

![Forest plot showing odds of a more favourable outcome for intervention groups compared with controls for outcomes reported at \>6 months to ≤12 months (drug risk outcome measures).\
The blue denotes significant effect in favour of the Intervention group. The grey denotes non-significant. The red denotes significant effect in the favour of the control group. CI, confidence interval.](pmed.1002890.g006){#pmed.1002890.g006}

![Forest plot showing odds of a more favourable outcome for intervention groups compared with controls for outcomes reported at last follow-up (drug risk outcome measures).\
The blue denotes significant effect in favour of the Intervention group. The grey denotes non-significant. The red denotes significant effect in the favour of the control group. CI, confidence interval.](pmed.1002890.g007){#pmed.1002890.g007}

Effect size calculations from single studies showed a significant intervention effect for other outcomes including alcohol misuse at ≤6 months (OR 3.97; 95% CI 2.26--6.96), 6--12 months (OR 2.90; 95% CI 1.66--5.06), and \>12 months (OR 1.77; 95% CI 1.00--3.13). There was a significant intervention effect at ≤6 months for change in well-being (OR 1.40; 95% CI 1.11--1.77) and HbA1c (OR 3.61; 95% CI 1.93--6.75). There was also a significant intervention effect for smoking cessation in adolescents at ≤6 months (OR 1.31; 95% CI 1.13--1.52), 6--12 months (OR 1.25; 95% CI 1.11--1.40), and \>12 months (OR 1.19; 95% CI 1.08--1.31). See [Fig 8](#pmed.1002890.g008){ref-type="fig"} and [Table 1](#pmed.1002890.t001){ref-type="table"}. No significant intervention effects were found for several outcomes of single studies, including physical activity, diet, weight loss, and screening.

![Forest plot showing odds for intervention groups compared with controls for outcomes reported at ≤6 months (other outcome measures).\
The blue denotes significant effect in favour of the Intervention group. The grey denotes non-significant. The red denotes significant effect in the favour of the control group. CI, confidence interval, HbA1c, haemoglobin A1c.](pmed.1002890.g008){#pmed.1002890.g008}

The strongest evidence for network intervention approach was for the individuals approach. Subgroup analyses provided evidence to support the individuals intervention approach for sexual health ([S2](#pmed.1002890.s012){ref-type="supplementary-material"}--[S4](#pmed.1002890.s014){ref-type="supplementary-material"} Figs) (\<6 months: 2.09 \[1.63, 2.67\] and 6--12 months: 1.62 \[1.35, 1.95\]) and drug risk ([S5](#pmed.1002890.s015){ref-type="supplementary-material"}--[S7](#pmed.1002890.s017){ref-type="supplementary-material"} Figs) (\<6 months: 4.68 \[2.20, 9.96\]). The results of all other subgroup analyses were not significant. Further details regarding the evidence for specific network intervention approaches are provided in the [S3 Text](#pmed.1002890.s004){ref-type="supplementary-material"}.

For sexual health outcomes, other subgroup analyses were significant for intervention length (*p* \> 0.05; [S8 Fig](#pmed.1002890.s018){ref-type="supplementary-material"}) at ≤6 months, mean age of participants at ≤6 months (*p* = 0.002; [S14 Fig](#pmed.1002890.s024){ref-type="supplementary-material"}), and percentage of female participants at \>12 months (*p* \< 0.001; [S22 Fig](#pmed.1002890.s032){ref-type="supplementary-material"}). The results of all other subgroup analyses were not significant.

For sexual health outcomes reported at ≤6 months, sensitivity analyses showed that there was a significantly higher pooled OR for studies with an attrition rate of below 20% versus studies with a higher attrition rate (*p* = 0.002; [S38 Fig](#pmed.1002890.s048){ref-type="supplementary-material"}). For sexual health outcomes reported at ≤6 months, sensitivity analyses also showed that there was a significantly higher pooled OR for studies that used RCT or cluster RCT (cRCT) designs versus studies that used any other design (*p* = 0.002; [S44 Fig](#pmed.1002890.s054){ref-type="supplementary-material"}). For sexual health outcomes reported at \>6 months to \<12 months or less, sensitivity analyses showed that there was a significantly higher pooled OR for studies that used RCT or cRCT designs versus studies that used any other design (*p* = 0.003; [S45 Fig](#pmed.1002890.s055){ref-type="supplementary-material"}). For drug risk outcomes reported at ≤6 months, sensitivity analyses showed that there was a significantly lower pooled OR for studies that used RCT or cRCT designs versus studies that used any other design (*p* \< 0.001; [S47 Fig](#pmed.1002890.s057){ref-type="supplementary-material"}). For all other analyses, sensitivity analyses showed that the pooled effect size estimate was robust to the omission of studies classified at high risk of bias, studies not conducting an ITT analysis, studies with high attrition rates, and studies using nonrandomised designs (see [S26](#pmed.1002890.s036){ref-type="supplementary-material"}--[S48](#pmed.1002890.s058){ref-type="supplementary-material"} Figs).

Visual inspection of funnel plots revealed little evidence of publication bias for the examined studies (see [S50](#pmed.1002890.s060){ref-type="supplementary-material"}--[S53](#pmed.1002890.s063){ref-type="supplementary-material"} Figs). Both the Egger and PEESE methods showed no evidence of small-study effects (*p* \> 0.05) at all time points for sexual health and drug risk outcomes. However, the results of these tests, and of the meta-analyses themselves, should be interpreted cautiously because of the high degree of heterogeneity.

Overall, 15 studies had low risk of bias, and 22 had high risk of bias, leading to an overall high risk of bias across the included studies. The most common problem areas were inadequate randomisation methods and a lack of control for contamination between groups. Details of the risk of bias assessment for all included studies are available in the [S1 Fig](#pmed.1002890.s011){ref-type="supplementary-material"}.

Discussion {#sec015}
==========

Findings from our review offer evidence of the effectiveness of social network interventions for health behaviours and outcomes. There is evidence to support both short-term (\<6 months) and longer-term effects (\>6 months), particularly for sexual health outcomes. Interventions using social network approaches support the repeated calls for health behaviour interventions to move beyond individual-level behaviour approaches \[[@pmed.1002890.ref022],[@pmed.1002890.ref023]\] to exploit network influences on behaviour that have been well documented in the literature. The strongest evidence of effectiveness for a network intervention approach was for the individuals approach. Subgroup analyses provided evidence to support this individual approach for sexual health (\<6 months: 2.09 \[1.63, 2.67\] and 6--12 months: 1.62 \[1.35, 1.95\]) and drug risk (\<6 months: 4.68 \[2.20, 9.96\]).

Encouragingly, social network interventions have been successful in reaching, retaining, and changing the behaviour of so-called hidden, hard-to-reach, and at-risk populations, including MSM, people who inject drugs (PIDs), and other priority populations (e.g., low-income or minority populations). Overall, the included studies demonstrated high participation and retention rates that are critical for these interventions, which aim to activate and stimulate network and social environment mechanisms that promote health. Theoretically, such interventions work by redefining social norms towards the avoidance of high-risk behaviours. Typically, social norms are formed by observing the behaviour of popular peers and then adopting and modelling these behaviours, which further spreads them to others in the network \[[@pmed.1002890.ref030]\].

The network interventions reviewed used or promoted existing network functions such as social identity, social support, social exchange, and social learning processes. Research has shown support for the social contagion theory \[[@pmed.1002890.ref031]\], which suggests that health outcomes, behaviours, and beliefs (e.g., obesity, happiness) are 'transmitted' through social networks \[[@pmed.1002890.ref032]\]. The employment of network theories and social--ecological models could build on the wealth of knowledge we have from individual-level models and their articulation of how social factors influence individual biology, beliefs, decisions, and behaviours. Furthermore, health behaviour interventions have traditionally been unsuccessful in achieving long-term maintenance of new behaviours; however, the important role of social networks in behaviour maintenance is evident in theories of habit formation (which emphasise the importance of external cues) \[[@pmed.1002890.ref033]\] and theories of maintained behaviour change (which emphasise the role of social norms in reinforcing new behaviours) \[[@pmed.1002890.ref034]\].

Notwithstanding the fact that the reviewed studies were of variable quality, fundamental methodological quality issues actually run much deeper, for the correct way to obtain unbiased effect estimates is not obvious and certainly nontrivial when individual observations fail the independence assumptions that are required for conventional analysis. Epidemiologists have only recently developed innovative methods to obtain valid estimates of putative causal effects, and the conceptual issues concerning control of confounding become somewhat more subtle in the presence of spill-over effects and interference \[[@pmed.1002890.ref035]\]. Valente's taxonomy of network intervention types was not specifically designed to correspond with putative mechanisms, as might be extracted from modern causal mediation analysis \[[@pmed.1002890.ref036]\]. Network interventions have also been criticised for lacking generalisability and being context specific, given that network structures and dynamics are often shaped by local settings and environments. Entirely new evaluation designs may be required, and the suggestions made so far involving sequential randomisation have not been practical \[[@pmed.1002890.ref037]\].

If social network interventions are to meaningfully inform public health policy and practice, then a number of implementation factors must be overcome in order to develop simple, cost-effective programmes. For example, innovative 'network-optimised interventions' are able to identify structurally influential individuals without mapping entire networks \[[@pmed.1002890.ref013]\].

One limitation of our review is the difficulty of isolating the effects of specific social network intervention components on health outcomes. The social network interventions included in this review may have included other active intervention components, and the studies were not typically designed to test causal effects of social network mechanisms or to differentiate the effects of the four types of network intervention approaches. As Tanner-Smith and Grant have suggested, network science itself may offer added value in synthesising the evidence for these different types of network interventions \[[@pmed.1002890.ref038]\]. Further studies are needed to rigorously evaluate different group-segmentation and leader-identification techniques and individuals network approaches such as identifying peripheral nodes, bridging nodes, and early adopters. The development of such interventions would benefit from the application of a multiphase optimization strategy (MOST) \[[@pmed.1002890.ref039]\], which uses a factorial experimental design to identify the unique effects, and interaction effects, of specific intervention components that could include social network approaches or other active components (e.g., educational material). This would help to inform the optimal design for assessing the effectiveness and cost-effectiveness of network interventions. Further limitations include the reliance on self-reported outcomes, which have inherent recall and desirability biases, and results obtained in studies of key populations may limit the generalisability of findings to other populations or groups.

The cost-effectiveness of network-based interventions has yet to be established. We hypothesise that such interventions would be cost-effective given their reliance on 'free' human capital and potential to increase the reach, effectiveness, and maintenance of health behaviour interventions \[[@pmed.1002890.ref040]\]. To the best of our knowledge, only one study conducted a cost-effectiveness analysis \[[@pmed.1002890.ref041]\], and it found the intervention to be cost-effective and is now implemented at scale using a social enterprise model \[[@pmed.1002890.ref042]\]. Kim and colleagues (2015) \[[@pmed.1002890.ref013]\] suggested that network interventions could be particularly useful in resource- and infrastructure-limited areas, where networks could be used to increase the number of people engaged or could enhance the spread and adoption of those interventions.

An additional priority for future research should be adolescent populations. The strong empirical evidence base for the association between social networks and health behaviours in adolescents has rarely been applied in interventions in this population, and we found only two studies among adolescent populations. Therefore, given the compelling evidence base, including strong evidence for peer influence on adolescent health behaviours, and rich information on social network mechanisms in well-defined social network structures (typically peer networks within school settings), this area is ripe for network-based interventions, which would bridge the gap between the empirical evidence and current intervention approaches. Furthermore, none of the included studies involved social networking platforms. The pervasive use of online social networking platforms, particularly in adolescents, may help drive evaluative and methodological innovation for network interventions. Social networking sites inherently have extant social networks and should be further explored, albeit in light of acknowledged ethical and implementation challenges \[[@pmed.1002890.ref043]\]. These platforms may hold promise for diffusion of information and 'simple' behaviour change \[[@pmed.1002890.ref044]\], although initial evidence suggests online social ties may have less impact on complex behaviour change \[[@pmed.1002890.ref045]\].

In summary, our systematic review and meta-analysis was reported in line with PRISMA, following a registered protocol and assessing risk of bias using a well-established tool to provide what we believe to be the first systematic review and meta-analysis of the effectiveness of social network interventions for a range of health outcomes. The evidence demonstrates that health and well-being are connected through complex and dynamic webs of social networks and that harnessing these networks may be especially important for health behaviour. However, existing health interventions rarely include components designed to explicitly use social network phenomena to maximise the adoption or diffusion of health-related information or behaviour. As evident from our review, social network interventions have demonstrated evidence of intervention effectiveness both in the short and long term, across a range of behaviours, settings, and populations. We argue that network phenomena are inherent in our interventions but are currently being overlooked and subsequently underused \[[@pmed.1002890.ref005]\]. In light of these findings, future research and health behaviour interventions should account for the social networks in which individuals are embedded.
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